Verrica Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Verrica Pharmaceuticals's earnings have been declining at an average annual rate of -19.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 30.4% per year.
Key information
-19.7%
Earnings growth rate
-2.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 30.4% |
| Return on equity | n/a |
| Net Margin | -922.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Verrica Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 9 | -85 | 65 | -4 |
| 30 Jun 24 | 14 | -87 | 70 | 0 |
| 31 Mar 24 | 9 | -81 | 59 | 0 |
| 31 Dec 23 | 5 | -67 | 47 | 0 |
| 30 Sep 23 | 3 | -48 | 33 | 15 |
| 30 Jun 23 | 9 | -23 | 17 | 0 |
| 31 Mar 23 | 9 | -23 | 17 | 0 |
| 31 Dec 22 | 9 | -24 | 17 | 0 |
| 30 Sep 22 | 9 | -28 | 19 | -13 |
| 30 Jun 22 | 1 | -41 | 23 | -9 |
| 31 Mar 22 | 0 | -43 | 26 | -5 |
| 31 Dec 21 | 12 | -35 | 27 | 0 |
| 30 Sep 21 | 12 | -39 | 32 | 15 |
| 30 Jun 21 | 12 | -36 | 28 | 16 |
| 31 Mar 21 | 12 | -34 | 26 | 16 |
| 31 Dec 20 | 0 | -43 | 25 | 16 |
| 30 Sep 20 | 0 | -37 | 19 | 17 |
| 30 Jun 20 | 0 | -33 | 18 | 15 |
| 31 Mar 20 | 0 | -31 | 16 | 16 |
| 31 Dec 19 | 0 | -28 | 15 | 15 |
| 30 Sep 19 | 0 | -28 | 14 | 16 |
| 30 Jun 19 | 0 | -28 | 13 | 17 |
| 31 Mar 19 | 0 | -26 | 12 | 16 |
| 31 Dec 18 | 0 | -21 | 9 | 13 |
| 30 Sep 18 | 0 | -20 | 6 | 9 |
| 30 Jun 18 | 0 | -15 | 3 | 7 |
| 31 Mar 18 | 0 | -11 | 2 | 4 |
| 31 Dec 17 | 0 | -10 | 1 | 4 |
Quality Earnings: 1NE is currently unprofitable.
Growing Profit Margin: 1NE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1NE is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.
Accelerating Growth: Unable to compare 1NE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1NE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 1NE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.